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A B S T R A C T
Introduction: Neuroinflammation is a potential player in neurodegenerative conditions, particularly the ag-
gressive ones, such as multiple system atrophy (MSA). Previous reports on cytokine levels in MSA using serum or
cerebrospinal fluid (CSF) have been inconsistent, including small samples and a limited number of cytokines,
often without comparison to Parkinson's disease (PD), a main MSA differential diagnosis.
Methods: Cross-sectional study of CSF levels of 38 cytokines using a multiplex assay in 73 participants: 39 MSA
patients (19 with parkinsonian type [MSAp], 20 with cerebellar type [MSAc]; 31 probable, 8 possible), 19 PD
patients and 15 neurologically unimpaired controls. None of the participants was under non-steroidal anti-
inflammatory drugs at the time of the lumbar puncture.
Results: There were not significant differences in sex and age among participants. In global non-parametric
comparisons FDR-corrected for multiple comparisons, CSF levels of 5 cytokines (FGF-2, IL-10, MCP-3, IL-12p40,
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MDC) differed among the three groups. In pair-wise FDR-corrected non-parametric comparisons 12 cytokines
(FGF-2, eotaxin, fractalkine, IFN-α2, IL-10, MCP-3, IL-12p40, MDC, IL-17, IL-7, MIP-1β, TNF-α) were sig-
nificantly higher in MSA vs. non-MSA cases (PD + controls pooled together). Of these, MCP-3 and MDC were the
most significant ones, also differed in MSA vs. PD, and were significant MSA-predictors in binary logistic re-
gression models and ROC curves adjusted for age. CSF levels of fractalkine and MIP-1α showed a strong and
significant positive correlation with UMSARS-2 scores.
Conclusion: Increased CSF levels of cytokines such as MCP-3, MDC, fractalkine and MIP-1α deserve considera-
tion as potential diagnostic or severity biomarkers of MSA.
1. Introduction
Multiple system atrophy (MSA) is a rapidly progressive neurode-
generative condition that can clinically present as parkinsonism (MSAp)
or cerebellar syndrome (MSAc), requiring dysautonomia for the clinical
diagnosis [1]. Definitive diagnosis necessitates the neuropathological
confirmation of glial cell alpha-synuclein inclusions in basal ganglia,
brainstem and cerebellar structures [1]. Accordingly, MSA is classified
as a synucleinopathy alongside Parkinson's disease (PD) raising the
concern that alpha-synuclein biomarkers might fail to differentiate both
conditions [2,3]. Thus, lately non-alpha-synuclein biomarkers of MSA
such as the light chain of neurofilament and coenzyme Q10 in per-
ipheral blood or cerebrospinal fluid (CSF) [4–8] have been investigated.
Another alternative is that of cytokines as a proxy of inflammatory
activity, with the hypothesis that the aggressiveness of MSA might be
related to greater neuro-inflammation compared to PD. Still, the in-
terpretation of cytokines changes is challenging, due to their wide range
of functions (proinflammatory, anti-inflammatory, unrelated to in-
flammation, unknown). Moreover, cytokines might show alterations in
other aggressive parkinsonisms and be non-specific markers. Up to now,
most published studies on cytokines levels in MSA have used peripheral
blood [9,10]. This biofluid poses the caveat of potential confound by
systemic inflammatory processes or drugs, such as non-steroidal anti-
inflammatory drugs (NSAIDs). Moreover, most of these studies have not
compared MSA to PD [10,11]. Conversely, CSF theoretically could
allow for more specifically assessing intrathecal processes. In the largest
CSF report published to date, 27 cytokines were assessed in 20 MSAc
cases and compared to 12 subjects with spinocerebellar ataxia (SCA)
and 15 non-inflammatory neurological controls, with main findings
being a similar proinflammatory profile in MSAc and SCA, associated
with the disease course in the case of MSAc.
In view of all this, we hypothesized that CSF cytokines would be
differently expressed in MSA subjects, not only relative to neurologi-
cally unimpaired controls, but also to PD patients, in spite of both MSA
and PD being synucleinopathies.
2. Methods
Design and setting: In this convenience cross-sectional pilot study
we used the demographic and clinical data along with the CSF samples
of patients from the Catalan MSA Registry (CMSAR). Patients were
recruited from several neurological centres in Catalonia (population 7.5
million), between March 2015 and February 2018, and diagnosed ac-
cording to the second consensus statement on MSA diagnosis [12]. The
data and CSF samples from PD and control subjects were obtained from
the Movement Disorders Biosample Collection of Hospital Clinic de
Barcelona (MDBC-HCB), a single centre biorepository consisting of
several biosamples including CSF. We have used part of these CSF
samples in previous studies [8,13]. All the samples from both the
CMSAR and the MDBC-HCB were collected, processed and analysed in a
centralized way at the coordinating centre (Hospital Clínic de Barce-
lona). Cases under NSAIDs at the time of lumbar puncture were ex-
cluded. Both the CMSAR and the MDBC-HCB along with the present
CSF biomarker study have received approval from the competing Ethics
Committee. All participants or their representatives signed a written
informed consent.
Demographical and clinical data: Movement disorders specialized
neurologists (DMG, APS, MJM) collected demographic and clinical
variables of all participants through the clinical history, the neurolo-
gical examination and the motor sections of the Unified Multiple
System Atrophy Rating Scale (UMSARS-2) [14] or the Unified PD
Rating Scale (UPDRS-3) [15], and the Hoehn and Yahr (H&Y) staging
[16]. The variables considered for this study were age at disease onset
and at inclusion, sex, disease duration, levodopa equivalent daily dose
(LEDD) [17], and the UMSARS-2 scores.
CSF sample collection: CSF samples were obtained via lumbar
puncture at the L2-L3 level with a 22-gauge needle, between 8 and 10
a.m. after overnight fasting and in off-medication condition. The first
2 mL were used for routine studies. The following 10 mL were, im-
mediately centrifuged at 4,000 g for 10 min and stored at −80 °C in
300 μL polypropylene aliquots until analysis. Only CSF samples with an
erythrocyte count of 0 were included.
CSF cytokines analysis: A premixed multiplex 38-bead assay, the
Human Cytokine and Chemokine Panel (HCYTMAG-60K-PX38;
Milliplex, Millipore, Billerica, MA, USA), was performed according to
the manufacturer's instructions using undiluted samples in a Luminex®
200 TM analyzer. All CSF samples were analysed in duplicate. The
concentration of each given cytokine for each study participant was
calculated as the mean of both duplicates, as usual. We determined 38
cytokines and chemokines: soluble CD40 ligand (sCD40L), epidermal
growth factor (EGF), eotaxin, fibroblast growth factor 2 (FGF-2), FMS-
like tyrosine kinase 3 ligand (Flt-3L), fractalkine, granulocyte colony
stimulating factor (G-CSF), GM-CSF, growth-regulated oncogene
(GRO), IFN-α2, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-
7, IL-8, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17A, IFN-γ-in-
duced protein 10 (IP-10/CXCL10), monocyte chemotactic proteins-1
and 3 (MCP-1/CCL2, MCP-3/CCL7), macrophage-derived chemokine
(MDC/CCL22), macrophage inflammatory proteins 1α and 1β (MIP-1α/
CCL3, MIP-1β/CCL4), transforming growth factor α (TGF-α), TNF-α
and β, and vascular endothelial growth factor (VEGF). Data acquisition
was performed using the Luminex® xPONENT® software. For statistical
analyses purposes, cases with undetectable levels in a given cytokine
were assigned the lowest value of the cohort for that particular cytokine
divided by two in order to be included in the comparative analyses.
Sample wells with bead counts below 35 were excluded from analysis
due to lesser reliability in their signal. Likewise, duplicates with a
coefficient of variation (CV) > 25% were excluded. Additionally, we
checked that there were not large differences in the proportion of un-
detectable cases or cases with < 35 beads or with CV > 25% among the
study groups.
Statistical plan and analysis: No formal power calculations were
carried out beforehand due to the rarity of MSA, with the number of
participants (greater than that from previous positive studies) being
deemed reasonable. Categorical variables are expressed as frequencies
and were compared using the χ2 square test or the Fisher exact test.
Continuous variables are expressed as median and interquartile range
(IQR). Kruskal-Wallis test was used for global comparisons followed by
Mann-Whitney's U test for pair-wise comparisons (MSA vs. PD, MSA vs.
controls, MSA vs. non-MSA (PD + controls), PD vs. controls and also
MSA-p vs. PD). All analyses (both comparisons, either global or pair-
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wise, and correlations) were corrected for multiple comparisons by
means of false discovery rate (FDR) [18] considering the number of
demographic and clinical variables in the descriptive part, and the
number of assessable cytokines (n = 37, since one cytokine was
undetectable in all cases, see further on) in the part of CSF cytokines
levels. Subsequently, we identified the most significant, corrected CSF
variables with data available for the larger part of the cohort as po-
tential MSA predictors (or independent variables) in binary logistic
Fig. 1. Box plots of CSF levels (in pg/mL) of FGF-2 [A], MCP-3 [B] and MDC [C] in global comparisons (MSA, PD, controls), of IL-12p40 [D], MCP-3 [E] and MDC [F]
in pair-wise comparison of MSA vs. non-MSA (PD + controls), as well as when comparing MSA vs. PD [G, H, I], and finally of MCP-3 and MDC in the pair-wise
comparison of MSA-p vs. PD [J, K].
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regression models with MSA diagnosis as outcome (dependent vari-
able). In these models the alternative outcome to MSA was either non-
MSA (PD patients + controls, as the cases without the target diagnostic,
as done in previous biomarkers studies) [2,8] or PD (the obvious dif-
ferential diagnosis for MSA and particularly MSA-p). Potential modi-
fiers, such as age and sex were included in the models, limiting the
number of covariates according to the size of the tested sample to avoid
overfitting. These binary logistic regression models resulted in the re-
spective odds ratios (OR) and their 95% confidence intervals (95%CIs).
We used the estimated probabilities from the binary logistic regression
model combining the CSF cytokines most significantly associated with
MSA and with data available for the better part of the cohort in a ROC
curve analysis to discriminate MSA vs. non-MSA (PD + controls) with
the respective area under the curve (AUCs) and its 95%CI. Additionally,
we run ROC curves for individual CSF levels of significant cytokines for
the discrimination of MSA from PD, and of MSA-p from PD. Linear
correlations between CSF cytokines levels and quantitative demo-
graphic and clinical data were further explored with Spearman's cor-
relation (also FDR-corrected for multiple comparisons). All statistical
tests were two-tailed, with significance threshold set at a p-value
≤0.05. Analyses were performed using IBM SPSS Statistics software,
version 24.0 (Armonk, NY: IBM Corp).
3. Results
Demographic and clinical comparisons (Table 1): We included 39
MSA patients (19 with parkinsonian type [MSAp], 20 with cerebellar
type [MSAc]; 31 probable, 8 possible, with all of them having been
reclassified as probable thereafter at follow-up), 19 PD patients and 15
neurologically unimpaired controls. There were no significant differ-
ences in sex and age. Disease duration was greater in PD vs. MSA. Side
effects of lumbar puncture were mild (transient headache, puncture site
pain) and rare (5%).
Multiplex assay performance: IL-3 was below the detection range in
all samples. Flt-3L, GRO, IL8, IP10 and MCP-1 were assessable in all
participants. There were no significant differences in the proportion of
undetectable cases and of those with < 35 beads or CV > 25% among
groups except for eotaxin, MCP-3 and VEGF (more frequently un-
detectable in PD and controls than in MSA), IL-2 (more cases with < 35
beads in MSA) and IL-1ra (more cases with CV > 25% in MSA) (Data
not shown).
Comparisons of CSF levels of cytokines (Table 1; Fig. 1; Suppl.
Table 1): In global non-parametric comparisons (Kruskal-Wallis test)
with FDR-correction for multiple comparisons, CSF levels of 5 cytokines
(FGF-2, IL-10, MCP-3, IL-12p40, MDC) differed among MSA, PD and
controls. In pair-wise comparison (Mann-Whitney's U test) with FDR-
correction for multiple comparisons, there were 12 cytokines (FGF-2,
eotaxin, fractalkine, IFN-α2, IL-10, MCP-3, IL-12p40, MDC, IL-17, IL-7,
MIP-1β, TNF-α) with significantly higher CSF levels in MSA than in
non-MSA (PD + control) cases. Of these, MCP-3, IL-12p40 and MDC
had FDR-corrected significantly higher CSF levels in MSA compared to
PD (with MCP-3 and MDC also retaining the significant difference in the
comparison limited to MSA-p vs. PD). When comparing MSA to con-
trols, IL-10, MCP-3 and MDC had FDR-corrected significantly higher
CSF levels in the former relative to the latter group. There were no
significant FDR-corrected differences in the CSF levels of any cytokine
in PD patients vs. controls. There were no FDR-corrected significant CSF
cytokines differences between MSAp and MSAc either (Data not
shown).
Adjusted binary logistic regression models and ROC curves (Table 2;
Fig. 2A; Suppl. Fig. 1A–B): CSF MCP-3 and MDC levels (Fig. 1) were
significantly associated with MSA vs. non-MSA in the respective binary
logistic regression models adjusting for age and sex. In a model com-
bining age at inclusion and both these cytokines, younger age and in-
creasing CSF levels of MCP-3 and MDC were significant predictors of
MSA vs. non-MSA. Accordingly, the ROC curve generated by using the
estimated probabilities from the aforementioned regression model
showed a significant discriminant ability of MSA vs. non-MSA of the
combination of decreasing age and increasing CSF levels of MCP-3 and
MDC. Additionally, CSF levels of either MCP-3 or MDC were predictive
of MSA vs. PD and of MSA-p vs. PD in the respective binary logistic
regression models and ROC curves.
Linear correlations in MSA: There were no FDR-corrected significant
correlations between CSF levels of cytokines and either age at onset, age
Table 2
Significant binary logistic regression models with different combinations of demographic and CSF variables as predictors (independent variables) and MSA or MSA-p
as outcome (dependent variable).
MSA vs. non-MSA Odds ratio 95% confidence interval p-value
Lower margin Upper margin
Model 1 (MSA, n = 35; non-MSA, n = 33) [total, n = 68]
Age at inclusion (in years) 0.88 0.90 0.96 0.007a
Sex (woman) 0.74 0.21 2.52 0.738
CSF MCP-3 levels (in pg/mL) 2.19 1.44 3.33 < 0.001a
MODEL 2 (MSA, n = 36; non-MSA, n = 31) [total, n = 67]
Age at inclusion (in years) 0.85 0.76 0.94 0.003a
Sex (woman) 1.34 0.34 5.23 0.675
CSF MDC levels (in pg/mL) 1.89 1.36 2.63 < 0.001a
MODEL 3 (MSA, n = 32; non-MSA, n = 30) [total, n = 62]
Age at inclusion (in years) 0.82 0.71 0.95 0.009a
CSF MCP-3 levels (in pg/mL) 2.05 1.28 3.29 0.003a
CSF MDC levels (in pg/mL) 2.21 1.33 3.68 0.002a
MSA vs. PD Odds ratio 95% confidence interval p-value
Lower margin Upper margin
MODEL 1 (MSA, n = 35; PD, n = 19) [total, n = 54]
CSF MCP-3 levels (in pg/mL) 1.81 1.26 2.61 0.001a
MODEL 2 (MSA, n = 37; PD, n = 17) [total, n = 54]
CSF MDC levels (in pg/mL) 1.54 1.16 2.05 0.003a
MSA-p vs. PD Odds ratio 95% confidence interval p-value
Lower margin Upper margin
MODEL 1 (MSA-p, n = 18; PD, n = 19) [total, n = 37]
CSF MCP-3 levels (in pg/mL) 1.75 1.15 2.67 0.009a
MODEL 2 (MSA-p, n = 18; PD, n = 17) [total, n = 35]
CSF MDC levels (in pg/mL) 1.80 1.19 2.74 0.006a
a = significant association. Note that for quantitative variables the ORs indicate the change in risk per each measure unit increase or decrease in the predictor.
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at inclusion, disease duration, or LEDD.
Conversely, the CSF levels of up to 17 of the 38 tested cytokines
(including 4 of the cytokines significantly differing between MSA and
non-MSA: FGF-2, fractalkine, IFN-α2 and IL-10) showed FDR-corrected
significant positive linear correlations with the UMSARS-2 scores
(Suppl. Table 2). These correlations were particularly significant in the
case of the CSF levels of fractalkine and also MIP-1α (Fig. 2B–C).
Additionally, there were significant FDR-corrected correlations
among several CSF cytokines levels in MSA patients. Those were mostly
positive correlations, as in the case of FGF-2 with both MCP-3 and IL-
12p40, of fractalkine with both IFN-α2 and IL-7, of IFN-α2 with both IL-
7 and IL-17, and of MIP-1β with both MCP-3 and TNF-α (Suppl.
Table 3).
4. Discussion
In this study CSF levels of several cytokines were increased in MSA
vs. PD and controls, although with variability in the detectability and
reliability of these measurements. Still, 12 of the 38 tested cytokines
were significantly increased in MSA compared to non-MSA cases, with
two of these (MCP-3 and MDC) being also significantly increased in the
pair-wise comparisons of MSA and MSA-p vs. PD and when comparing
MSA with controls, being significant predictors of MSA in binary re-
gression models and ROC curves too. CSF levels of fractalkine and of
MIP-1α also showed significant and positive correlations with the
UMSARS-2 scores. All this suggests that these CSF cytokines levels
could be diagnostic or severity markers for MSA and assist the differ-
entiation between MSA and PD, which is challenging with current
alpha-synuclein biomarkers.
The interpretation of our findings, consisting of a mixture of pro-
and anti-inflammatory cytokines, is largely speculative from a me-
chanistic point of view. Still, and not forgetting that these are “markers”
and not “makers”, it cannot be ruled out that at the time of CSF col-
lection, there was a mixed expression of pro-inflammatory cytokines
(pointed to play a role early in the disease) and anti-inflammatory ones
(which might be the result of secondary compensatory mechanisms)
[19]. In fact, our top significant MSA predictors (CSF levels of MCP-3
and MDC) have a pro-inflammatory and an anti-inflammatory profile
each.
We are unaware of previous studies having assessed MCP-3 (or
CCL7) in MSA. Nevertheless, this cytokine that has pro-inflammatory
and chemotactic properties and that was markedly increased in CSF of
our MSA patients compared to both PD patients and controls, has been
previously pointed to be a differentiation factor for midbrain dopami-
nergic precursors and neurons and might therefore be connected with
degenerative parkinsonisms such as MSA [20].
Our other top candidate CSF cytokine to differentiate MSA from
non-MSA, MDC, also known as C–C motif chemokine ligand 22
(CCL22), and its receptor have been associated with recruitment of T-
cells in chronic inflammatory processes. MDC has been implicated in a
number of diseases, including experimental autoimmune encephalitis
[21]. Ours is the first study measuring CSF levels of MDC in MSA.
Another of the other CSF cytokines significantly increased in our
MSA patients, IL-10 (an anti-inflammatory cytokine involved in the
interactions between microglia, astrocytes and neurons) [22], only
differed between MSA patients and controls, but not between MSA and
PD participants, who had non-significantly higher levels than controls.
This finding is similar to those from two previous studies using serum
instead of CSF [8,23]. Specifically in the study by Brodacki et al., IL-10
levels in atypical parkinsonisms were in between those of PD and
controls, but only two patients with MSA were included [8]. Another
study found CSF levels of IL-10 to be lower in MSA-C and spinocer-
ebellar ataxias (SCA), but compared to other non-inflammatory neu-
rological disorders, rather than non-neurological controls or other
parkinsonisms (neither MSA-P nor PD were included) [11]. As elevated
IL-10 is anti-inflammatory and can be potentially neuroprotective in the
acute phase of ischaemic stroke [24], its increase in MSA and PD may
reflect compensatory mechanisms.
Of the other CSF cytokines significantly increased in MSA, FGF-2
and IL-12p40 showed remarkable differences in global and MSA vs.
non-MSA comparisons, respectively. The association of FGF-2 and IL-
12p40 with synucleinopathies such as MSA is biologically plausible.
Regarding FGF, it has been found to promote alpha-synuclein expres-
sion [25], but also to protect the nigrostriatal system from 6-hydroxi-
dopamine [26]; hence, its increase in MSA might be either a result of
the synucleinopathy itself or a compensatory attempt to protect
Fig. 2. [A] ROC curve generated with the estimated probabilities from the
binary logistic regression model including age at inclusion and CSF levels of
both MCP-3 and MDC in combination to discriminate MSA from non-MSA; [B]
FDR-corrected significant positive linear correlation between the CSF levels of
fractalkine and UMSARS-2 scores; [C] FDR-corrected significant positive linear
correlation between the CSF levels of MIP-1α and UMSARS-2 scores.
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neurons. IL-12p40 on the other hand has been recently associated with
PD subtypes, albeit with higher levels implying a more benign pheno-
type [27], whereas in our case its levels were increased in MSA, which
is more aggressive than PD.
Fractalkine (C-X3-C-motif chemokine ligand 1; CX3CL1), which
showed a strong positive correlation with high (i.e., worse) UMSARS-2
scores, is a chemokine constitutively expressed in neurons that, to-
gether with its receptor CX3CR1 (expressed in microglia), is thought to
play a crucial role in mediating neuron-microglia communications in
the CNS. Fractalkine has been reported to have both neuroprotective/
anti-inflammatory and neurotoxic/proinflammatory properties in sev-
eral experimental models of neurological disorders. Such dual activities
might be dependent on disease stage and the degree of microglial ac-
tivation [28–31]. In contrast to our results, CSF levels of fractalkine did
not differ between patients with PD, MSA and controls in a previous
study by Shi and colleagues, where CSF levels of Flt-L3 were sig-
nificantly reduced in MSA vs. PD [32] unlike in our study. Potential
explanations for these discrepancies are different methodological
techniques and populations, as well as the design more focused in PD in
Shi et al.‘s study and in MSA in our case. Two other studies have not
found differences in Flt-L3 either [33,34].
While MIP-1β was among the CSF cytokines increased in MSA (but
not the most significant one), the other cytokine strongly correlating
with UMSARS-2 scores along with fractalkine was MIP-1α (macrophage
inflammatory protein 1α, or CCL3). This pro-inflammatory cytokine
might be of potential interest since its levels were increased in a re-
cently reported mouse model of MSA [35]. However, to the best of our
knowledge its levels in a biofluid from MSA patients had not been
previously reported to correlate with clinical measures of these patients
as in our study.
The main comparison of our study is to be made with the one by
Yamasaki et al. [11]. As mentioned before, in that study 27 cytokines
were assessed only in MSAc and only compared to SCA and neurolo-
gical controls, and whether or not samples were tested in duplicate was
not specified. The main results were increases in CSF levels of IL-6, IL-7,
IL-12, IL-13, and GM, and decreases in FGF-2, VEGF, IL-1β, IL-2, IL-4,
IL-5, IL-8, IL-10, IL-15, MIP-1β, and TNF-α in MSA-C and SCA vs.
neurological controls [11]. Additionally, MCP-1 negatively correlated
with disease duration and IL8 and IL-1 with the UMSARS-2. CSF levels
of IL6 were associated with the hot cross bun sign in brain MRI [11]. In
contrast to Yamasaki et al., and as mentioned above we have found
positive correlations between UMSARS-2 and CSF levels of both anti-
inflammatory (fractalkine) and pro-inflammatory (MIP-1α) cytokines,
suggesting a link between inflammation and clinical severity of the
degenerative parkinsonism. These differences in results might be due to
different ethnicities and patients (only MSAc vs. SCA in Yamasaki
et al.'s; both MSAp and MSAc vs. PD in our study) indicating that more
work needs to be done in this area.
This study is not without limitations. MSA participants had estab-
lished disease limiting our interpretation to advanced rather than early
cases. The PD and control groups were relatively small and, in the case
of PD, with longer disease duration than MSA. Thus, we cannot exclude
bias due to disease duration, which could not be included as a covariate
in regression models due to insufficient sample size. Nevertheless, dis-
ease duration did not correlate with the CSF levels of any of the tested
cytokines. This study lacks a validation cohort, and has no neuro-
pathological confirmation of most cases. However, all three cases au-
topsied since study completion have been confirmed as MSA. The re-
gional setting compromises generalization as variation among
ethnicities might be relevant (for example compared to prior East Asian
studies). Furthermore, CSF was collected only at baseline, and all
analyses are cross-sectional. Finally, we included eight possible MSA
cases, but all have been thereafter reclassified as probable. Hence, if
any, the effect of inclusion of possible MSA cases might have been an
under- rather than an overestimation of CSF cytokines differences.
Our study also has strengths. It is the largest MSA sample with the
greatest number of CSF cytokines assessed to date. We investigated both
MSAp and MSAc and compared them not only to PD (a main differential
diagnosis considering that both conditions are synucleinopathies), but
also to a group of individuals without known neuropsychiatric pa-
thology. Another advantage over part of previous studies is the de-
termination of cytokines in CSF and the exclusion of cases treated with
NSAIDs. Moreover, the collection and handling of the samples was
centralized. Laboratory technicians who run the multiplex technique
were blind to the clinical diagnoses. Additionally, the findings were
corrected for multiple comparisons and adjusted for potential modi-
fiers.
In summary, our findings suggest that several CSF levels of cyto-
kines are increased in MSA, with the combination of age at assessment
and CSF levels of MCP-3 and MDC showing potential as diagnostic
markers of MSA, while CSF levels of fractalkine and MIP-1α strongly
correlated with UMSARS-2 scores. Larger studies with validation co-
horts and longitudinal assessments, as well as comparison to other
atypical parkinsonisms, are warranted to further evaluate the CSF levels
of these cytokines as diagnostic or severity markers in MSA.
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